Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes

2017 ◽  
Vol 19 (4) ◽  
pp. 482-488
Author(s):  
Niels Porksen ◽  
Helle Linnebjerg ◽  
Parag Garhyan ◽  
Eric C. Q. Lam ◽  
Mary P. Knadler ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Sensitivity ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Affect Insulin Sensitivity

scholarly journals Advances in Basal Insulin Therapy

2016 ◽  
Vol 32 (6) ◽  
pp. 260-268
Author(s):  
Jennifer Goldman ◽  
John R. White
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Data Extraction ◽  
The United States ◽  
Insulin Degludec ◽  
Study Selection ◽  
Meta Analyses

Objective: To review 2 new basal insulin analogs that have been approved in the United States for use in type 1 and type 2 diabetes—insulin glargine 300 units/mL and insulin degludec 100 units/mL and 200 units/mL. Data Sources: PubMed was searched using the terms “insulin glargine 300 units/mL,” “Gla-300,” “insulin degludec,” “IDeg,” “insulin degludec 200 units/mL,” and “insulin degludec 100 units/mL” for articles published between 1995 and May 2016. Study Selection and Data Extraction: Clinical trials, meta-analyses and subanalyses were identified; review articles were excluded. Relevant citations from identified articles were also reviewed. Data Synthesis: The new basal insulins, insulin glargine 300 units/mL and insulin degludec 100 units/mL and 200 units/mL, have improved pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 units/mL. All demonstrate longer durations of action, beyond 24 hours, and less variability. These improved profiles translate into comparable A1C reductions and comparable, or improved, levels of hypoglycemia compared to insulin glargine 100 units/mL. Conclusions: These benefits may lead to improved glycemic control in a range of patients with type 1 and type 2 diabetes with true once-daily dosing.

scholarly journals Long-Term Efficacy of Insulin Glargine After Switching from NPH Insulin as Intensive Replacement of Basal Insulin in Japanese Diabetes Mellitus. Comparison of Efficacy between Type 1 and Type 2 diabetes (JUN-LAN Study 1.2)

2007 ◽  
Vol 54 (6) ◽  
pp. 975-983 ◽  
Author(s):  
Yoshie KANAZAWA ◽  
Yasuhiro IGARASHI ◽  
Koji KOMIYA ◽  
Yuko SAKURAI ◽  
Tomoaki SHIMIZU ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Nph Insulin ◽  
Term Efficacy

scholarly journals Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

2017 ◽  
Vol Volume 10 ◽  
pp. 273-284 ◽  
Author(s):  
Ip Tim Lau ◽  
Ka Fai Lee ◽  
Wing Yee So ◽  
Kathryn Tan ◽  
Vincent Yeung
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Glargine ◽  
Insulin Therapy ◽  
Basal Insulin

Insulin Glargine: A New Basal Insulin

2002 ◽  
Vol 36 (6) ◽  
pp. 1019-1027 ◽  
Author(s):  
Terri L Levien ◽  
Danial E Baker ◽  
John R White ◽  
R Keith Campbell
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Nph Insulin ◽  
Once Daily ◽  
Nocturnal Hypoglycemia ◽  
Acting Insulin ◽  
Long Acting

OBJECTIVE: To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine. DATA SOURCES: Primary and review articles regarding insulin glargine were identified by MEDLINE search (1966–July 2001); abstracts were identified through Institute for Scientific Information Web of Science (1995–July 2001) and the American Diabetes Association. Additional information was obtained from the insulin glargine product information. STUDY SELECTION AND DATA EXTRACTION: All of the articles and meeting abstracts identified from the data sources were evaluated, and all information deemed relevant was included in this review. Priority was placed on data from the primary medical literature. DATA SYNTHESIS: Insulin glargine is a long-acting, recombinant human insulin analog that is given once daily as a basal source of insulin in patients with type 1 or type 2 diabetes mellitus. Modification of the basic insulin structure has produced a new insulin that is soluble at an acidic pH, but precipitates in the subcutaneous tissue and is slowly released from a depot. Insulin glargine has a slower onset of action than NPH insulin and a longer duration of action with no peak activity. Once-daily administration of insulin glargine has comparable efficacy to that of NPH insulin administered once or twice daily in basal-bolus regimens when used in combination with intermittent doses of regular insulin or insulin lispro in patients with type 1 and type 2 diabetes, and in conjunction with oral antidiabetic agents in patients with type 2 diabetes. Overall, insulin glargine has an incidence of hypoglycemia comparable to or less than that of NPH insulin, with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin seen in some studies. CONCLUSIONS: Insulin glargine is a long-acting insulin analog capable of providing 24-hour basal insulin coverage when administered once daily at bedtime. Its activity profile, which lacks a pronounced peak, more closely resembles that of endogenous basal insulin than that of other intermediate- or long-acting insulins and appears more likely to be associated with a reduced incidence of hypoglycemia, particularly nocturnal hypoglycemia. Insulin glargine physiologically provides basal insulin but, for most patients, the addition of a rapid-acting insulin, like insulin lispro, before or with meals will need to be included in the treatment regimen to achieve optimal management of blood glucose concentrations.

scholarly journals Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

2016 ◽  
Vol 18 ◽  
pp. 50-58 ◽  
Author(s):  
K. Cusi ◽  
A. J. Sanyal ◽  
S. Zhang ◽  
B. J. Hoogwerf ◽  
A. M. Chang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Liver Enzymes ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content

scholarly journals Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog

2010 ◽  
Vol 3 ◽  
pp. CMED.S5330 ◽  
Author(s):  
Jason R. Young ◽  
Carrie Mcadam-Marx
Keyword(s):  
Type 2 Diabetes ◽  
Weight Gain ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Insulin Detemir ◽  
Nph Insulin ◽  
Long Acting

Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin detemir has generally but not consistently demonstrated less weight gain than insulin glargine in T2DM. The benefits of basal insulin analogs relative to NPH insulin are well recognized, including less FBG variability, lower risk of hypoglycemia, and less weight gain specifically with insulin detemir. However, NPH insulin continues to be widely prescribed, which may be due in part to economic considerations. While NPH insulin generally costs less per prescription, insulin detemir has been shown to be cost effective compared to NPH insulin as well as insulin glargine. Therefore, insulin detemir is an effective option from both clinical and economic perspectives for patients with T1DM or T2DM who require basal insulin to achieve glycemic control.

The efficacy and safety of LY2963016 among patients with Type 1 and Type 2 diabetes previously treated with insulin glargine

2015 ◽  
Vol 10 (S 01) ◽  
Author(s):  
D Dahl ◽  
LB Lacaya ◽  
RK Pollom ◽  
LL Ilag ◽  
JS Zielonka
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Efficacy And Safety ◽  
Previously Treated

Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients (Pts) with Type 2 Diabetes (T2DM) on Basal Insulin Supported Oral Therapy (BOT)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1020-P ◽  
Author(s):  
JOCHEN SEUFERT ◽  
ANDREAS FRITSCHE ◽  
HELMUT ANDERTEN ◽  
KATRIN PEGELOW ◽  
STEFAN PSCHERER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Therapy ◽  
Nocturnal Hypoglycemia

2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2192-PUB
Author(s):  
STEWART B. HARRIS ◽  
FRANK J. SNOEK ◽  
LUIGI MENEGHINI ◽  
FELIPE LAUAND ◽  
JUKKA WESTERBACKA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Randomized Controlled Trials ◽  
Real World ◽  
Basal Insulin ◽  
Treatment Satisfaction ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Switching the basal insulin to insulin glargine 300 U/ ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety

2021 ◽  
Author(s):  
Jochen Seufert ◽  
Peter Wiesli ◽  
Andreas Fritsche ◽  
Helmut Anderten ◽  
Katrin Pegelow ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Therapy ◽  
Observational Trial
Sign in / Sign up

Export Citation Format

Share Document